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All-cause and cause-specific mortality from restrictive and obstructive spirometric 
patterns in Chinese adults with and without dyspnea: Guangzhou Biobank Cohort 
Study 
 
Short title: mortality from restrictive and obstructive spirometric patterns with dyspnea  
  
Abstract 
Objective To study whether abnormal spirometric patterns were associated with differential 
mortality in Chinese adults with and without dyspnea.  
Methods Guangzhou Biobank Cohort Study (GBCS) participants were classified by 
spirometric patterns and presence of dyspnea into 6 groups: normal spirometry (NS), 
restriction on spirometry (ROS) and airflow obstruction (AO), each with and without dyspnea. 
Adjusted hazard ratios (aHRs) were calculated for mortality using Cox models. 
Results Among 16777 subjects, 1595 (9.5%) had ROS, 1036 (6.2%) had AO and1009 (6.0%) 
had dyspnea. A total of 1993 deaths (11.9%) occurred during 11-year follow-up. Using NS 
without dyspnea as reference, NS with dyspnea was significantly associated with increased 
cardiovascular mortality risk (aHRs 1.61 (95% confidence interval (CI) 1.18-2.19); ROS with 
and without dyspnea were associated with increased risks of all-cause (aHRs 1.46 (95% CI 
1.28-1.66) and 1.81(95% CI 1.33-2.47)) and cardiovascular mortality (aHRs 1.89 (95% CI 
1.55-2.31) and 1.85 (95% CI 1.12-3.03)), but not of lung cancer mortality (aHRs 1.33 (95% 
CI 0.91-1.94) and 1.35 (95% CI 0.49-3.70)); AO with and without dyspnea were associated 
with increased risks of all-cause (aHRs 1.59 (95% CI 1.36-1.86) and 2.36 (95% CI 
1.77-3.15)), cardiovascular (aHRs 1.43 (95% CI 1.08-1.90) and 1.61(95% CI 0.91-2.82)) and 
lung cancer mortality (aHRs 1.91 (95% CI 1.29-2.84)and 3.01(95% CI 1.46-6.23)). These 
associations did not vary by sex or smoking status (all P-values for interaction >0.05). 
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Conclusion: Both ROS and AO, with and without dyspnea, were associated with increased 
all-cause and cardiovascular disease mortality. The increased risk of all-cause was greater and 
that of cardiovascular mortality was lower for AO than ROS. AO showed significantly 
increased risk of lung cancer but ROS did not. (272 words) 
Keywords 
Restriction on spirometry, Airflow obstruction, Dyspnea, Mortality 
 
Introduction  
Chronic obstructive pulmonary disease (COPD), characterised by airflow obstruction (AO), 
is the third leading cause of mortality worldwide[1]. The China Pulmonary Health (CPH) 
study reported an overall COPD prevalence of 8.6% among adults aged 20 years or older 
during 2012-2015, estimated to affect about 100 million Chinese[2]. Restriction on 
spirometry (ROS) is also associated with increased mortality risk[3-8]. The prevalence of 
ROS varied from 6.5% to 21.0% in United States populations[9-16], and from 8.0% to 12.3% 
in Asian populations[17, 18]. A few cohort studies have compared the risks of mortality from 
AO and ROS, but the results were inconsistent. Some studies found that both AO and ROS 
were associated with higher risk of all-cause mortality compared to those with normal lung 
function[3, 6, 7, 9, 11, 19, 20], while other studies showed that only ROS, but not AO, was 
significantly associated with all-cause and cardiovascular mortality[5], or that only recurrent 
AO was associated with higher lung cancer mortality[6].  
 
A nationally representative survey of adults by the Chinese Centre for Disease Control and 
Prevention showed that around two-thirds of COPD patients were asymptomatic[21]. Among 
respiratory symptoms, the level of dyspnea has been found to be superior in predicting 
mortality in those with COPD[22, 23] and in the general population[24-28].  
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We studied the relationships between abnormal spirometric patterns and dyspnea with 
subsequent all-cause and cause-specific mortality in a cohort of Chinese adults after 11-year 
follow-up. 
 
Methods 
Study participants  
The Guangzhou Biobank Cohort Study (GBCS) is a three-way collaboration among the 
Guangzhou No. 12 Hospital, the Universities of Hong Kong and Birmingham. The cohort 
study was set up in 2003-8, inviting members of the Guangzhou Health and Happiness 
Association for the Respectable Elders’ (GHHARE) to take part. GHHARE is a community 
social and welfare association with branches throughout Guangzhou. GHHARE is open for 
membership to any permanent Guangzhou residents aged 50 years or older. GBCS recruited 
30430 members of GHHARE who agreed to take part. Members were not eligible if they 
were non-ambulatory, were receiving chemotherapy or radiotherapy for cancer, or dialysis 
for renal failure[29]. Due to cultural reasons, female members were more likely to respond 
and were over-represented in the GBCS. GBCS study was approved by Guangzhou Medical 
Ethics Committee of the Chinese Medical Association. All participants gave written informed 
consent before participation. Trained interviewers used a standardized computer-based 
questionnaire to collect information on demographic characteristics, education level, smoking 
status, childhood and adulthood exposure to passive smoking at home, passive smoking 
exposure at work, occupational dust and fume exposure, daily cooking oil fume exposure, 
installed fume extraction system, and personal disease history of hypertension, diabetes 
mellitus (DM), cancer and cardiovascular disease (CVD). Standard physical examination 
included assessment of body weight, height, waist circumference and blood pressure using 
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validated instruments. Blood glucose, white blood cell count and lipids were assayed after an 
overnight (>8 hours) fast. Dyslipidaemia was defined as plasma triglycerides ≥1.7 mmol/L, 
high-density lipoprotein (HDL)-cholesterol <1.00 mmol/L in men and <1.30 mmol/L in 
women, or self-reported use of lipid-lowering medication. Hypertension was defined as 
systolic blood pressure ≥140mmHg, diastolic blood pressure ≥90mmHg, or self-reported use 
of antihypertensive medication. DM was defined as fasting glucose ≥7.0 mmol/L and/or 
self-reported DM.  
 
Exposure indicators  
Spirometry was done with a pneumotachograph (Chestgraph HI-701, Chest MI Inc, Tokyo, 
Japan) in phase I recruitment from September 2003 to October 2004, a turbine flowmeter 
(Cosmed microQuark, Rome, Italy) in phase II recruitment from April 2005 to May 2006 and 
two ultrasonic flowmeters (ndd Medical Technologies Easy-on PC; Zurich, Switzerland) in 
phase Ⅲrecruitment from September 2006 to January 2008. Details of the methods have 
been reported elsewhere[30, 31]. Briefly, the pulmonary function test with at least three 
manoeuvres was conducted in a standing position following standard procedures, and the best 
measure of forced expiratory volume in 1 sencond (FEV1) and forced vital capacity (FVC) 
were recorded. Predicted values and the fifth percentile of FEV1 and FVC were derived using 
the equations developed by Ip and colleagues for Chinese populations[32]. We used a 
numerical quality-check algorithm developed according to European Respiratory Society 
recommendations and criteria[33] to classify tests for reliability and validity. The remaining 
results were assessed by visual inspection of flow-volume and volume-time curves. 
Spirometry outcomes were classified into 3 categories: normal spirometry (NS): FEV1/FVC 
ratio ≥lower limits of normal (LLN, the fifth percentile of FEV1 and FVC by Ip [32]) and 
FVC % predicted (% predicted=observed/predicted x100%) ≥LLN; AO: FEV1/ FVC ratio 
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<LLN and ROS: FEV1/ FVC ratio ≥LLN and FVC % predicted <LLN. For comparability 
with other studies, spirometry outcomes were also classified based on the fixed ratio criteria 
for sensitivity analysis: NS: FEV1/FVC ≥0.70, FVC% predicted ≥0.80; AO: FEV1/FVC <0.70 
and ROS: FEV1/FVC ≥0.70, FVC% predicted <0.80.  
 
The British modified Medical Research Council (mMRC) dyspnea questionnaire has been 
prioritised by the Global initiative for COPD (GOLD) for assessing COPD exacerbation and 
mortality, and was therefore used in this study. The presence of dyspnea was defined as 
mMRC dyspnea scale >2 (felt shortness of breath while walking with other people of the 
same age or after walking a few minutes on level ground, during dressing or undressing, or at 
rest).  
 
Participants were classified into 6 mutually exclusive groups according to spirometric 
patterns and presence of dyspnea: NS without dyspnea as the reference group, NS with 
dyspnea, ROS without dyspnea, ROS with dyspnea, AO without dyspnea and AO with 
dyspnea.  
 
Study outcomes 
Vital status of participants on 31st December 2017 and the date and the underlying causes of 
death were obtained using record linkage with the Guangzhou Centre for Disease Control and 
Prevention (GZCDC). Follow-up duration was calculated from the date of first visit until the 
date of death or December 2017 for survivors. Causes of death were coded by trained 
nosologist in each hospital according to the International Classification of Disease, 10th 
Revision (ICD-10). ICD-10 I00–I99 was classified as cardiovascular mortality and C34 as 
lung cancer mortality. Cross-checking of past medical history against verbal autopsy (VA) 
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was conducted to improve the quality of coding. VA has been shown to yield reasonably 
reliable estimates of the broad cause of death in adults in China[34].  
 
Statistical analysis 
The baseline demographic and clinical characteristics were analyzed by the mean (±standard 
deviation (SD)) for continuous values and as percentages of the total number of subjects in 
the groups for categorical variables. Continuous variables were analyzed using one way 
analysis of variance (ANOVA) for three groups. Categorical variables were compared using 
chi-square test. Plots of the log–log survival curves were used to assess the proportional 
hazards assumptions. Cox proportional hazard models were used to calculate the adjusted 
hazard ratio (aHR) of all-cause and cause-specific mortality for ROS and AO with and 
without dyspnea. Age, sex, waist circumference, education (≤primary, middle school and ≥
college), smoking (never, former, current smokers with 0-29 pack-years and current smokers 
with 30+ pack-years), childhood and adulthood exposure to passive smoking at home, 
passive smoking exposure at work, occupational dust and fume exposure, daily cooking oil 
fume exposure, installed fume extraction system, white blood cell count, hyperlipidemia, 
hypertension, DM and history of CVD and cancer were included in the models. 10 multiple 
imputations were performed using chained equation to predict missing data based on all other 
variables, and the HRs of each imputed data set were estimated and combined to produce an 
overall estimate of HR using the Rubin rule[35]. Interactions between the spirometric 
patterns and the presence of dyspnea were assessed, and stratified analysis by spirometric 
patterns and dyspnea was conducted in line with GOLD recommendation[22] and biological 
plausibility that both indexes were reported to have independent impact on mortality[9, 26]. 
Sex and smoking status interactions were assessed and stratified analyses were conducted 
separately. We further performed sensitivity analyses for spirometric patterns based on the 
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fixed ratio criteria. All tests of significance were 2-tailed, with P <0.05 as statistically 
significant. All analyses were performed using Stata / SE 15.0 (StataCorp LP, 4905 Lakeway 
Drive, College Station, TX77845 USA). 
 
Results  
After excluding 13278 GBCS participants with invalid spirometry measurements, 194 
participants with missing vital status data and181 participants with missing dyspnea data, we 
included 16777 subjects with valid exposure and outcome indicators in the present study 
(Figure 1). The mortality of the participants included in this study (11.9%) was slightly lower 
than that of those excluded (15.2%). The mean age (±SD) of included participants was 61.4 
(±7.3) years, and 1009 (6.0%) of them had >=Grade 2 dyspnea. 1595 (9.5%) participants 
had ROS and 1036 (6.2%) had AO based on LLN criteria. Table 1 shows that participants 
with ROS and AO were older and had lower education level and higher prevalence of 
dyspnea and general obesity than those with NS. Those with ROS had longer waist 
circumference, lower high density lipoprotein cholesterol, higher white blood cell count, and 
higher prevalence of central obesity, hypertension and DM than those with AO and NS. They 
also had higher prevalence of CVD than those with NS. Participants with AO were more 
likely to have ever smoked, had lower triglyceride, lower prevalence of hyperlipidemia and 
higher prevalence of underweight than those with ROS and NS.  
 
We recorded 1993 (11.9%) deaths during an average of 11.1(±2.2)-year follow-up, including 
699 cardiovascular and 252 lung cancer deaths. Compared to the reference group of NS 
without dyspnea, NS with dyspnea was significantly associated with increased cardiovascular 
mortality risk (aHR 1.61 (95% confidence interval (CI) 1.18-2.19), while ROS with and 
without dyspnea were associated with increased all-cause (aHRs 1.46 (95% CI 1.28-1.66) and 
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1.81(95% CI 1.33-2.47) respectively) and cardiovascular (aHRs 1.89 (95% CI 1.55-2.31) and 
1.85 (95% CI 1.12-3.03)) mortality risks. There was no significant association with lung 
cancer mortality risk (aHRs 1.33 (95% CI 0.91-1.94) and 1.35 (95% CI 0.49-3.70)). AO with 
and without dyspnea were associated with increased all-cause (aHRs 1.59 (95% CI 1.36-1.86) 
and 2.36 (95% CI 1.77-3.15) respectively), cardiovascular (aHRs 1.43 (95% CI 1.08-1.90) 
and 1.61(95% CI 0.91-2.82)) and lung cancer (aHRs 1.91 (95% CI 1.29-2.84) and 3.01(95% 
CI 1.46-6.23)) mortality risks (Figure 1-2).  
 
The interaction term between the spirometric patterns and the presence of dyspnea was 
non-significant for all-cause, cardiovascular and lung cancer mortality, with the P values for 
interaction ranging from 0.18 to 0.44. In the whole cohort, ROS was associated with higher 
risk of all-cause (aHR 1.47, 95% CI 1.31-1.66) and cardiovascular mortality (aHR 1.81, 95% 
CI 1.50-2.19), but not with lung cancer mortality (aHR 1.33, 95% CI 0.93-1.91). AO was 
associated with higher risk of all-cause (aHR 1.68, 95% CI 1.46-1.94), cardiovascular (aHR 
1.40, 95% CI 1.08-1.82) and lung cancer mortality (aHR 2.07, 95% CI 1.45-2.97). Dyspnea 
was associated with higher risk of all-cause (aHR 1.36, 95% CI 1.17-1.59) and cardiovascular 
mortality (aHR 1.43, 95% CI 1.12-1.82), but not with lung cancer mortality (aHR 1.23, 95% 
CI 0.79-1.94). Stratified analyses showed similar relationships between abnormal spirometric 
patterns and mortality in participants with and without dyspnea (Appendix table 1). The 
association between dyspnea and mortality varied in different spirometric patterns: it 
remained significant only in those with AO for all-cause mortality and in those with NS for 
cardiovascular mortality (Appendix table 2). 
 
There were no significant interactions by sex or smoking status, and the P values for 
interaction ranging from 0.40 to 0.97. The stratified analyses showed similar tendencies 
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(Appendix figure 3-4). Sensitivity analyses based on fixed ratio criteria showed similar 
patterns (Appendix figure 1-2 and 5-6). 
 
Discussion 
We found that ROS, AO and dyspnea were all independently associated with increased 
all-cause and cardiovascular mortality risk in a cohort of older Chinese after 11-year 
follow-up. Presence of dyspnea combined with spirometric abnormality increased mortality 
risk. AO with and without dyspnea had greater increased risks for all-cause mortality but 
lower risks for cardiovascular mortality than ROS. Furthermore, AO, but not ROS nor 
dyspnea, was associated with significantly increased risk for lung cancer mortality.  
 
COPD is the third leading cause of mortality worldwide[1], but its impact on cardiovascular 
mortality remains controversial. ROS is still under-diagnosed and underestimated in clinical 
settings. Several population studies including the National Health and Nutrition Examination 
surveys (NHANES)[9, 10] , the Atherosclerosis Risk in Communities (ARIC)[20] , COPD 
Gene[12], the Cardiovascular Health Study (CHS)[11] , Health Aging, and Body 
Composition (Health ABC)[13] , the Multi-Ethnic Study of Atherosclerosis 
(MESA)-Lung[14], Jackson Heart Study[15], the Tucson Epidemiological Study of Airway 
Obstructive Disease (TESAOD)[16], Singapore Longitudinal Ageing Studies (SLAS)[17] and 
Korea National Health and Nutrition Examination Survey (KNHANES)[18] have shown that 
the prevalence of ROS were similar to that of AO, varying from 6.5% to 21.0%. ROS was 
also reported to be associated with increased risks of co-morbidity and mortality[3-8]. The 
associations of both AO and ROS with all-cause mortality in general population were 
compared by a few previous studies[3, 5, 6, 9, 11, 20, 36], but only two studies reported the 
risks of cause-specific mortality, and the results were inconsistent[5, 6]. The Yamagata study 
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showed that ROS, instead of AO, was an independent predictor of all-cause and 
cardiovascular mortality[5]. On the other hand, the TESAOD study found recurrent and 
inconsistent ROS and recurrent AO, but not inconsistent AO, were associated with 
cardiovascular mortality[6]. In keeping with our findings, the TESAOD study also reported 
that only recurrent AO was associated with higher risk of lung cancer mortality[6].  
 
The precise mechanisms to explain these findings are unknown, but chronic muscle wasting, 
systematic inflammation and oxidative stress in COPD patients may be responsible for the 
increased all cause and CVD mortality risks[37, 38]. On the other hand, the higher percentage 
of smokers and older age of participants with AO are also the risk factors for lung cancer, 
which may explain the observed relationship. The demographic and clinical characteristics of 
ROS such as higher percentage of obesity, hypertension and DM were also risk factors for 
cardiovascular disease, and these might be responsible for the higher risk of cardiovascular 
mortality for ROS. Nevertheless, such risks remained significant after controlling for all these 
variables, indicating the independent associations of abnormal spirometric patterns regardless 
of these risk factors.  
 
An interesting finding of our study was that the mortality risk associated with dyspnea varied 
by spirometric patterns. Dyspnea was reported to be independently associated with increased 
all-cause and cardiovascular mortality[24, 25]. Our study showed similar associations and 
further found dsypnea was not associated with lung cancer mortality. 
Vlagtwedde/Vlaardingen study showed the all-cause and cardiovascular mortality risks 
associated with dyspnea were highest seen in subjects with an above median FEV1% 
predicted than that for those with a below median FEV1% predicted[24]. The ARIC study 
showed that respiratory symptoms predicted higher mortality in those with normal pulmonary 
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function[20]. Stratified analyses in our study showed increased cardiovascular mortality risk 
in those with normal spirometry, but the increased all-cause mortality risk only remained 
significant in those with AO. The ARIC study used a wide definition of respiratory symptoms 
including having cough, sputum production, wheezing and dyspnea. The percentages of 
symptomatic participants ranged from 20.6% to 81.9% in different spirometric patterns[20]. 
In contrast, the proportion with dyspnea ranged from 5.0% to 18.5% in our study and may 
explain some of the contrasting findings[20] . Nevertheless, our findings suggested that a 
combination of symptom and spirometric abnormality could identify subjects with higher 
mortality risk more accurately. 
 
The 13th Five-year Plan for Sanitation and Health of the People’s Republic China promotes 
spirometry screening as a regular health test. Nevertheless, the United States Preventive 
Services Task Force (USPSTF) review and recommendations[39], the United Kingdom 
National screening committee and GOLD[22] recommend against spirometry screening for 
COPD in asymptomatic patients because of inadequate evidence of its efficiency for directing 
clinical decisions or improving outcomes. Our study did not provide evidence of clinical 
benefit of spiromtry screening, but it demonstrated that AO in itself is associated with poorer 
outcome, indicating there is potential to early intervention.  
 
Our study had several strengths. It was based on a large population-based cohort of 
approximately 17000 older Chinese with 11-year follow-up. Of 9 studies exploring similar 
questions, only two had about 15000 participants[20, 36], while the sample size of other 
studies ranged from 1265 to 5542[3-6, 11, 19]. Only 3 studies had followed their participants 
for more than 22 years[4, 6, 9]. Most previous studies had adjusted for shared risk factors 
including age, sex, BMI and smoking[3-6, 11, 19, 20, 36], but none of them had more 
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information on other risk factors such as education level, dust and fume exposure, passive 
smoking exposure, inflammation, central obesity, hypertension, CVD, DM and cancer. The 
availability of such comprehensive data on risk factors for sensitivity analysis and adjustment 
was a strength. We also examined a range of outcomes, including all-cause, cardiovascular 
and lung cancer mortality. In contrast, most previous studies had only examined all-cause 
mortality and only 2 included cardiovascular mortality and lung cancer mortality[5, 6] .  
Furthermore, we used LLN as our primary measure for defining spirometric abnormalities, to 
minimize potential misclassification of subjects with normal pulmonary function. 
Nevertheless our findings were robust to alternative fixed ratio definitions of spirometric 
abnormality. We found that a surrogate outcome including both spirometry, a physiology 
measurement, and dyspnea, a patient-centred measurement, is associated with higher risk of 
mortality. This is consistent with American Thoracic Society and European Respiratory 
Society recommendations for COPD patients[40], but is seldom applied to general population. 
Only 2 previous studies had studied the mortality risk for a combination of both 
measurements[9, 20].     
 
However, our study had some limitations. First, the definition of restriction was based on 
FVC instead of total lung capacity. Sub-maximal inspiratory effort could lead to low FVC, 
which might lead to overinclusion of the number of participants with reduced lung volume. 
However, plethysmography, the only conclusive test to identify truly restricted subjects is not 
feasible to use in large population studies. Second, ROS could resolve and relapse 
inconsistently over time. We used spirometry at baseline, but not longitudinal data to classify 
spirometric patterns. Several serial follow-up spirometry tests can better identify cases with 
persistent ROS. The TESAOD study for example, classified participants with ROS at 
baseline into consistent or inconsistent ROS groups based on the presence of ROS at least 
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half, or less than half of follow-up surveys respectively, which we were not able to replicate. 
However, they found similar mortality risk in both groups[6]. Third, we did not have 
post-bronchodilator lung function data so could not identify those with reversible AO. 
Nevertheless, those with self-reported asthma have been excluded to minimize inclusion of 
post-bronchodilator spirometry. Among previous studies exploring the association between 
spirometric patterns and mortality, only SaRA study performed post-bronchodilator 
spirometry[3]. Fourth, 16777 participants included in our study had lower mortality overall 
than 13653 participants who were excluded, mainly due to invalid spirometry. Patients with 
more severe AO are likely to be overrepresented in those with invalid spirometry, so potential 
for selection bias and underestimation of the effect size could not be fully ruled out. 
 
Conclusions 
Our cohort study of older Chinese in the community showed that AO with and without 
dyspnea had greater increased mortality risks for all-cause but lower risks for cardiovascular 
disease than ROS with and without dyspnea. AO showed significantly increased risk of lung 
cancer but ROS did not. The associations of dyspnea with mortality varied by spirometric 
patterns. These findings emphasize the value of combining dyspnea symptom and pulmonary 
function in assessing respiratory health and predicting mortality outcomes. Screening with 
spirometry in asymptomatic subjects is not recommended in international guidelines because 
of inadequate evidence of health benefits. However, our study showed that even among those 
with no dyspnea symptom, the presence of AO is associated with higher all cause and lung 
cancer mortality risk than those with no spirometric abnormality. Our findings demonstrate 
that AO in itself is associated with poorer outcomes, so there might be potential to intervene. 
Furthermore, preliminarily assessment of respiratory health in the general population with the 
easy-to-use mMRC dyspnea questionnaires before performing spirometry might be an 
16 
 
efficient method to identify people with higher risk of mortality who could be targeted for 
interventions. 
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Table 1. Baseline demographic and clinical characteristics by spirometric patterns 
 Normal 
spirometry 
Restriction on 
spirometry 
Airflow 
obstruction  
P value 
N  14146 1595 1036  
Male, n (%) 3651 (25.8) 445 (27.9) 295 (28.5) 0.06 
Age, years, mean±SD 61.0±7.2 63.7±7.2a 63.7±7.6a <0.001 
Education, n (%)   a a <0.001 
≤ Primary 5480 (38.8) 846 (53.1) 533 (51.5)  
Junior middle 7379 (52.2) 642 (40.1) 425 (41.0)  
≥ Senior middle 1284 (9.1) 106 (6.7) 78 (7.5)  
Waist circumference, cm, 
mean±SD 
78.3±8.8 81.8±9.8a,b 77.4±9.4a <0.001 
Central obesity, n (%) 4583 (32.4) 756 (47.4)a,b 322 (31.1) <0.001 
BMI, kg/m2, mean±SD 23.8±3.2 24.3±3.7a,b 22.9±3.6a, <0.001 
BMI groups, n (%)  a,b a, <0.001 
Underweight  537 (3.8) 77 (4.8) 102 (9.9)  
Normal  5274 (37.3) 526 (33.0) 462 (44.6)  
Overweight  6958 (49.2) 750 (47.1) 389 (37.6)  
Obesity  1369 (9.7) 240 (15.1) 83 (8.0)  
IPAQ, n (%)£  a  <0.001 
Low  669 (6.5) 41 (3.9) 44 (5.5)  
Middle   2957 (28.9) 370 (35.2) 242 (30.1)  
High  6604 (64.6) 640 (60.9) 518 (64.4)  
Smoking status, n (%)  a,b a, <0.001 
Never 11629 (82.5) 1242 (78.0) 722 (70.0)  
Former 1128 (8.0) 172 (10.8) 155 (15.0)  
Current (0-29 pack-years) 373 (2.7) 23 (1.4) 42 (4.1)  
Current (≥30 pack-years) 962 (6.8) 156 (9.8) 113 (11.0)  
Passive smoking exposure, n (%)    
  Childhood home exposure 8417 (59.8) 908 (57.1) 588 (57.1) 0.04 
  Adulthood home exposure 7542 (53.6) 873 (54.8) 523 (50.7) 0.12 
  Work exposure 7362 (52.4) 784 (49.3) 529 (51.4) 0.06 
Occupational exposure, n (%)     
  Dust exposure 5088 (36.1) 637 (40.1) 407 (39.5) 0.001 
  Fume exposure 3869 (27.5) 441 (27.8)    286 (27.8) 0.95 
Cooking oil fume exposure, n (%)    
  Daily cooking  13887 (98.9) 1561 (98.6) 1021 (99.5) 0.07 
  Fume extraction system  9634 (68.8) 1064 (67.4) 637 (62.3)  <0.001 
Triglyceride, mmol/L 1.73±1.32 1.79±1.31b 1.56±1.00 a <0.001 
HDL-cholesterol, mmol/L, 
mean±SD 
1.66±0.41 1.63±0.39a,b 1.69±0.40 a <0.001 
LDL-cholesterol, mmol/L, 
mean±SD 
3.35±0.71 3.26±0.75a 3.25±0.67a, <0.001 
Fasting glucose, mmol/L, 
mean±SD 
5.69±1.58 6.07±2.18b 5.62±1.50a <0.001 
Systolic blood pressure, mmHg, 
mean±SD 
129±22 135±23a,b 130±23 <0.001 
Diastolic blood pressure, mmHg, 
mean±SD 
73±11 75±12a,b 72±11 <0.001 
White blood cell count, 6.3±1.6 6.7±1.6a,b 6.5±1.7a <0.001 
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SD, standard deviation; BMI, body mass index; IPAQ, International Physical Activity  
Questionnaire; HDL, high density lipoprotein; LDL, low density lipoprotein; CVD, 
cardiovascular disease; FEV1, forced expiratory volume in 1 second; FVC, forced vital 
capacity; LLN, lower limits of normal; 
% predicted= (observed/predicted) *100% 
Central obesity: waist circumference ≥90 cm in men or ≥80 cm in women 
Underweight: BMI < 18.5 kg/m2 Normal: 18.5 ≤BMI < 24 kg/m2 Overweight: 24 ≤BMI < 28 
kg/m2 Obesity: BMI ≥28 kg/m2 
Normal spirometry: FEV1/FVC ≥LLN, FVC% predicted ≥LLN 
Restriction on spirometry: FEV1/FVC ≥LLN, FVC% predicted <LLN 
Airflow obstruction: FEV1/FVC <LLN 
Dyspnoea: the British modified Medical Research Council dyspnoea scale ≥2 
£: only 12085 participants with valid data 
a: P <0.05 versus normal spirometry 
b: P <0.05 versus airflow obstruction 
 
109/L, mean±SD 
History of CVD, n (%) 650 (4.6) 98 (6.1)a 53 (5.1) 0.02 
History of cancer, n (%) 253 (1.8) 38 (2.4)a 19 (1.8) 0.25 
Co-morbidity, n (%)     
Hyperlipidemia 7295 (52.1) 844 (53.8) 485 (47.1) 0.002 
Hypertension 5650 (40.0) 824 (51.7)a,b 421 (40.7) <0.001 
Type 2 Diabetes mellitus 1574 (11.2) 289 (18.2)a,b 108 (10.5) <0.001 
Dyspnoea, n (%)  737 (5.2) 143 (9.0)a 129 (12.5)a <0.001 
FEV1% predicted, %, 
mean±SD 
98.7±14.1 67.7±11.5a 68.0±21.1a <0.001 
FVC% predicted, %, 
mean±SD 
95.9±13.3 64.0±9.9a,b 84.6±23.0a, <0.001 
FEV1/FVC, %, mean±SD 80.4±5.5 81.5±7.6
 a,b 61.5±8.2a, <0.001 
Mortality, n (%)     
   All-cause mortality 1424 (10.1) 336 (21.1) 233 (22.5) <0.001 
   Cardiovascular mortality 481 (3.4) 150 (9.4) 68 (6.6) <0.001 
   Lung cancer mortality 177 (1.3) 37 (2.3) 38 (3.7) <0.001 
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Figure 1 Flow diagram of participants  
GBCS, Guangzhou Biobank Cohort Study; LLN, lower limits of normal 
Normal spirometry: FEV1/FVC ≥LLN, FVC% predicted ≥LLN 
Restrictive on spirometry: FEV1/FVC ≥LLN, FVC% predicted <LLN 
Airflow obstruction: FEV1/FVC <LLN 
Dyspnoea: the British modified Medical Research Council dyspnoea scale ≥2 
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Figure 1 Kaplan-Meier analysis of subjects with NS, ROS and AO with or without dyspnea 
for all-cause, cardiovascular and lung cancer mortality.  
NS, normal spirometry; w/, with; w/o, without; ROS, restriction on spirometry; AO, airflow 
obstruction.  
NS: FEV1/FVC ≥LLN, FVC% predicted ≥LLN 
ROS: FEV1/FVC ≥LLN, FVC% predicted <LLN 
AO: FEV1/FVC <LLN 
Log-rank test for all-cause mortality, P <0.001  
Log-rank test for cardiovascular mortality, P <0.001 
Log-rank test for lung cancer mortality, P <0.001 
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Figure 2. Adjusted hazard ratio (HR) of mortality from Cox proportional hazard models by 
spirometric patterns and presence of dyspnea.  
Reference group: subjects with normal spirometry and without dyspnea (risk of 1).  
Models adjusted for sex, age, waist circumference, education, smoking status with pack-year, 
childhood and adulthood exposure to passive smoking at home, passive smoking exposure at 
work, occupational dust and fume exposure, daily cooking oil fume exposure, installed fume 
extraction system, white blood cell count, hyperlipidemia, hypertension, diabetes mellitus and 
history of cardiovascular disease and cancer. 
NS, normal spirometry; w/, with; w/o, without; ROS, restriction on spirometry; AO, airflow 
obstruction. 
NS: FEV1/FVC ≥LLN, FVC% predicted ≥LLN 
 
 
24 
 
ROS: FEV1/FVC ≥LLN, FVC% predicted <LLN 
AO: FEV1/FVC <LLN 
*: P <0.05; **: P<0.01; ***: P<0.001. 
 
Appendix table 1 Mortality rate (per 10000 person-years) and risk of all-cause and 
cause-specific mortality (from Cox proportional hazard models) in the whole cohort and 
stratified by presence of dyspnea  
 Person-
years  
All-cause mortality Cardiovascular mortality Lung cancer mortality 
 Rate  HR (95% CI) Rate  HR (95% CI) Rate  HR (95% CI) 
All         
 NS  157267 90.5 1.00 30.6 1.00 11.3 1.00 
 ROS 17954 187.1 1.47 (1.31-1.66)*** 83.5 1.81 (1.50-2.19)*** 20.6 1.33 (0.93-1.91) 
 AO 11084 210.2 1.68 (1.46-1.94)*** 61.4 1.40 (1.08-1.82)* 34.3 2.07 (1.45-2.97)*** 
        
Without dyspnea       
 NS  149233 89.0 1.00 29.1 1.00 11.3 1.00 
 ROS  16425 178.4 1.45 (1.28-1.65)*** 81.0 1.88 (1.54-2.29)*** 20.1 1.31 (0.90-1.91) 
 AO 9830 186.2 1.59 (1.36-1.85)*** 56.0 1.42 (1.07-1.88)* 30.5 1.90 (1.28-2.83)** 
        
With dyspnea       
 NS  8033 119.5 1.00 57.3 1.00 11.2 1.00 
 ROS  1529 281.2 1.89 (1.28-2.81)** 111.2 1.49 (0.81-2.77) 26.2 1.93 (0.51-7.21) 
 AO 1254 398.9 1.94 (1.33-2.83)** 103.7 1.01 (0.52-1.99) 63.8 4.81 (1.56-14.86)** 
Adjusted for sex, age, waist circumference, education, smoking status with pack-year, 
childhood and adulthood exposure to passive smoking at home, passive smoking exposure at 
work, occupational dust and fume exposure, daily cooking oil fume exposure, installed fume 
extraction system, white blood cell count, hyperlipidemia, hypertension, diabetes mellitus and 
history of cardiovascular disease and cancer. 
HR, hazard ratio; NS, normal spirometry; ROS, restriction on spirometry; AO, airflow 
obstruction; w/, with; w/o, without. 
NS: FEV1/FVC ≥LLN, FVC% predicted ≥LLN 
ROS: FEV1/FVC ≥LLN, FVC% predicted <LLN 
AO: FEV1/FVC <LLN 
P for dyspnea interaction: (1) all-cause mortality: 0.38; (2) cardiovascular mortality: 0.18; (3) 
lung cancer mortality: 0.44. 
*: P <0.05; **: P <0.01; ***: P <0.001. 
 
Appendix table 2 Mortality rate (per 10000 person-years) and risk of all-cause and 
cause-specific mortality (from Cox proportional hazard models) in the whole cohort and 
stratified by spirometric patterns 
 Person-
years 
All-cause mortality Cardiovascular mortality Lung cancer mortality 
 Rate  HR (95% CI) Rate  HR (95% CI) Rate  HR (95% CI) 
All         
 w/o dyspnea  175489 102.8 1.00 35.5 1.00 13.2 1.00 
 w/ dyspnea 10816 174.7 1.36 (1.17-1.59)*** 70.3 1.43 (1.12-1.82)** 19.4 1.23 (0.79-1.94) 
        
NS         
 w/o dyspnea  149233 89.0 1.00 29.1 1.00 11.3 1.00 
 w/ dyspnea 8033 119.5 1.17 (0.95-1.44) 57.3 1.55 (1.14-2.11)** 11.2 0.94 (0.48-1.84) 
        
ROS         
 w/o dyspnea  16425 178.4 1.00 81.0 1.00 20.1 1.00 
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 w/ dyspnea 1529 281.2 1.38 (0.98-1.93) 111.2 1.10 (0.65-1.88) 26.2 1.21 (0.41-3.61) 
        
AO        
 w/o dyspnea  9830 186.2 1.00 56.0 1.00 30.5 1.00 
 w/ dyspnea 1254 398.9 1.57 (1.12-2.19)** 113.7 1.37 (0.72-2.63) 63.8 1.46 (0.62-3.39) 
Adjusted for sex, age, waist circumference, education, smoking status with pack-year, 
childhood and adulthood exposure to passive smoking at home, passive smoking exposure at 
work, occupational dust and fume exposure, daily cooking oil fume exposure, installed fume 
extraction system, white blood cell count, hyperlipidemia, hypertension, diabetes mellitus and 
history of cardiovascular disease and cancer. 
HR, hazard ratio; NS, normal spirometry; ROS, restriction on spirometry; AO, airflow 
obstruction; w/, with; w/o, without. 
NS: FEV1/FVC ≥LLN, FVC% predicted ≥LLN 
ROS: FEV1/FVC ≥LLN, FVC% predicted <LLN 
AO: FEV1/FVC <LLN 
P for spirometry interaction: (1) all-cause mortality: 0.38; (2) cardiovascular mortality: 0.18; 
(3) lung cancer mortality: 0.44. 
*: P <0.05; **: P <0.01; ***: P <0.001 
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Appendix figure 1 Kaplan-Meier analysis of subjects with NS, ROS and AO based on fixed 
ratio criteria with or without dyspnea for all-cause, cardiovascular and lung cancer mortality.  
NS, normal spirometry; w/, with; w/o, without; ROS, restriction on spirometry; AO, airflow 
obstruction.  
NS: FEV1/FVC ≥0.70, FVC% predicted ≥0.80 
ROS: FEV1/FVC ≥0.70, FVC% predicted <0.80 
AO: FEV1/FVC <0.70 
Log-rank test for all-cause mortality, P <0.001  
Log-rank test for cardiovascular mortality, P <0.001 
Log-rank test for lung cancer mortality, P <0.001 
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Appendix figure 2. Adjusted hazard ratio (HR) of mortality from Cox proportional hazard 
models by spirometric patterns based on fixed ratio criteria and presence of dyspnea.  
Reference group: normal spirometry and without dyspnea (risk of 1).  
Models adjusted for sex, age, waist circumference, education, smoking status with pack-year, 
childhood and adulthood exposure to passive smoking at home, passive smoking exposure at 
work, occupational dust and fume exposure, daily cooking oil fume exposure, installed fume 
extraction system, white blood cell count, hyperlipidemia, hypertension, diabetes mellitus and 
history of cardiovascular disease and cancer. 
NS, normal spirometry; w/, with; w/o, without; ROS, restriction on spirometry; AO, airflow 
obstruction. 
NS: FEV1/FVC ≥0.70, FVC% predicted ≥0.80 
ROS: FEV1/FVC ≥0.70, FVC% predicted <0.80 
AO: FEV1/FVC <0.70 
*: P <0.05; **: P<0.01; ***: P<0.001. 
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Appendix figure 3. Adjusted hazard ratio (HR) of mortality from Cox proportional hazard 
models by spirometric patterns and presence of dyspnea in men and women.  
Reference group: normal spirometry and without dyspnea (risk of 1).  
Models adjusted for age, waist circumference, education, smoking status with pack-year, 
childhood and adulthood exposure to passive smoking at home, passive smoking exposure at 
work, occupational dust and fume exposure, daily cooking oil fume exposure, installed fume 
extraction system, white blood cell count, hyperlipidemia, hypertension, diabetes mellitus and 
history of cardiovascular disease and cancer. 
NS, normal spirometry; w/, with; w/o, without; ROS, restriction on spirometry; AO, airflow 
obstruction. 
NS: FEV1/FVC ≥LLN, FVC% predicted ≥LLN 
ROS: FEV1/FVC ≥LLN, FVC% predicted <LLN 
AO: FEV1/FVC <LLN 
P for sex interaction: (1) all-cause mortality: 0.50; (2) cardiovascular mortality: 0.57; (3) lung 
cancer mortality: 0.46. 
*: P <0.05; **: P<0.01; ***: P<0.001. 
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Appendix figure 4. Adjusted hazard ratio (HR) of mortality from Cox proportional hazard 
models by spirometric patterns and presence of dyspnea in ever and never smokers.  
Reference group: normal spirometry and without dyspnea (risk of 1).  
Models adjusted for sex, age, waist circumference, education, childhood and adulthood 
exposure to passive smoking at home, passive smoking exposure at work, occupational dust 
and fume exposure, daily cooking oil fume exposure, installed fume extraction system, white 
blood cell count, hyperlipidemia, hypertension, diabetes mellitus and history of 
cardiovascular disease and cancer. 
NS, normal spirometry; w/, with; w/o, without; ROS, restriction on spirometry; AO, airflow 
obstruction. 
NS: FEV1/FVC ≥LLN, FVC% predicted ≥LLN 
ROS: FEV1/FVC ≥LLN, FVC% predicted <LLN 
AO: FEV1/FVC <LLN 
P for sex interaction: (1) all-cause mortality: 0.97; (2) cardiovascular mortality: 0.40; (3) lung 
cancer mortality: 0.41. 
*: P <0.05; **: P<0.01; ***: P<0.001 
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Appendix figure 5. Adjusted hazard ratio (HR) of mortality from Cox proportional hazard 
models by spirometric patterns based on fixed ratio criteria and presence of dyspnea in men 
and women.  
Reference group: normal spirometry and without dyspnea (risk of 1).  
Models adjusted for age, waist circumference, education, smoking status with pack-year, 
childhood and adulthood exposure to passive smoking at home, passive smoking exposure at 
work, occupational dust and fume exposure, daily cooking oil fume exposure, installed fume 
extraction system, white blood cell count, hyperlipidemia, hypertension, diabetes mellitus and 
history of cardiovascular disease and cancer. 
NS, normal spirometry; w/, with; w/o, without; ROS, restriction on spirometry; AO, airflow 
obstruction. 
NS: FEV1/FVC ≥0.70, FVC% predicted ≥0.80 
ROS: FEV1/FVC ≥0.70, FVC% predicted <0.80 
AO: FEV1/FVC <0.70 
P for sex interaction: (1) all-cause mortality: 0.92; (2) cardiovascular mortality: 0.18; (3) lung 
cancer mortality: 0.32. 
*: P <0.05; **: P<0.01; ***: P<0.001. 
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Appendix figure 6. Adjusted hazard ratio (HR) of mortality from Cox proportional hazard 
models by spirometric patterns based on fixed ratio criteria and presence of dyspnea in ever 
and never smokers.  
Reference group: normal spirometry and without dyspnea (risk of 1).  
Models adjusted for sex, age, waist circumference, education, childhood and adulthood 
exposure to passive smoking at home, passive smoking exposure at work, occupational dust 
and fume exposure, daily cooking oil fume exposure, installed fume extraction system, white 
blood cell count, hyperlipidemia, hypertension, diabetes mellitus and history of 
cardiovascular disease and cancer. 
NS, normal spirometry; w/, with; w/o, without; ROS, restriction on spirometry; AO, airflow 
obstruction. 
NS: FEV1/FVC ≥0.70, FVC% predicted ≥0.80 
ROS: FEV1/FVC ≥0.70, FVC% predicted <0.80 
AO: FEV1/FVC <0.70 
P for sex interaction: (1) all-cause mortality: 0.67; (2) cardiovascular mortality: 0.26; (3) lung 
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cancer mortality: 0.68. 
*: P <0.05; **: P<0.01; ***: P<0.001 
